miR-372  inhibits p62 in head and neck squamous cell carcinoma  in vitro  and  in vivo

Li-Yin Yeh; Chung-Ji Liu; Yong-Kie Wong; Christine Chang; Shu-Chun Lin; Kuo-Wei Chang

doi:10.18632/oncotarget.3340

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

miR-372 inhibits p62 in head and neck squamous cell carcinoma in vitro and in vivo

Li-Yin Yeh, Chung-Ji Liu, Yong-Kie Wong, Christine Chang, Shu-Chun Lin and Kuo-Wei Chang _

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2015; 6:6062-6075. https://doi.org/10.18632/oncotarget.3340

Metrics: PDF 2449 views | HTML 2816 views | ?

Abstract

Li-Yin Yeh1, Chung-Ji Liu2,3, Yong-Kie Wong2,4, Christine Chang1, Shu-Chun Lin1,2,5 and Kuo-Wei Chang1,2,5

1 Institute of Oral Biology, National Yang-Ming University, Taipei, Taiwan

2 Department of Dentistry, National Yang-Ming University, Taipei, Taiwan

3 Department of Dentistry, Taipei Mackay Memorial Hospital, Taipei, Taiwan

4 Department of Dentistry, Taichung Veterans General Hospital, Taichung, Taiwan

5 Department of Stomatology, Taipei Veterans General Hospital, Taipei, Taiwan

Correspondence to:

Shu-Chun Lin, email:

Kuo-Wei Chang, email:

Keywords: Carcinoma, Hypoxia, Invasion, miR-372, Mouth

Received: November 26, 2014 Accepted: January 05, 2015 Published: January 21, 2015

Abstract

Here we showed that exogenous miR-372 expression and knockdown of p62 (sequestosome1 or SQSTM1), both increased migration of head and neck squamous cell carcinoma (HNSCC) cells. p62 induced phase II detoxification enzyme NADPH quinone oxidoreductase 1 (NQO1), which decreased ROS levels and cell migration. Also, miR-372 decreased p62 during hypoxia, thus increasing cell migration. Levels of miR-372 and p62 inversely correlated in human HNSCC tissues. Plasma levels of miR-372 was associated with advanced tumor stage and patient mortality. Both plasma and salivary miR-372 levels were decreased after tumor resection. We conclude that miR-372 decreases p62, thus increasing ROS and motility in HNSCC cells.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 3340

Publication Alerts

Post-Publication Promotion

Publication Discount

Research Papers:

miR-372 inhibits p62 in head and neck squamous cell carcinoma in vitro and in vivo

Abstract